Attana’s technology contributes to increased understanding of E. Coli pathogenesis
In the paper Yang et al shows how interaction between the bacteria and their specific target receptors can be altered. This can enable the future development of effective drugs or vaccines against infection by E. coli K1.
The experimental results showed significantly reduced adherence and invasion of the modified bacterial strain compared to the parent strain. Thereby enabling them to avoid fusing with lysosomes in cells.
Kinetic interaction studies with Attana Cell™ 200 demonstrated in detail that O-acetylated PSA from the modified bacteria interacted less and weaker with human sialic acid-binding immunoglobulin-like lectins (Siglecs), as compared to PSA of the parent strain. O-acetylated PSA also suppressed the production of Siglec-mediated proinflammatory cytokines.
Blockage of bacterial adherence to human macrophage-like cells by siglec-specifc monoclonal antibodies demonstrated the importance of Siglec-11 and Siglec- 14 for the parental strain to adhere to cells. Mice in vivo experiments as well as previous research indicates that O-acetylated PSA affects the infectiousness of the E. Coli K1 in both positive and negative direction. Hence, the current paper suggests that not only the O-acetylated PSA in itself is important, but also that the degree and sterical site has significant impact.
In summary these data concludes that that O-acetylation of K1 capsule is a strategy used by E. coli K1 to regulate its virulence. Consequently, new drugs or vaccines that can regulate O-acetylated PSA can potentially be used to specific treatment of E. Coli K1
Read the full publication here: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653822/
For more information, please contact:
Teodor Aastrup, CEO
teodor.aastrup@attana.com
+46 (0)8 674 57 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.
About Attana
Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com
Tags:
